The pharmaceutical industry's approach to Plasmodium vivax malaria has undergone significant transformation as stakeholders recognize the parasite's unique challenges and commercial potential. This neglected tropical disease, affecting over 200 million people annually, presents distinct market opportunities driven by unmet medical needs and evolving treatment paradigms...